BRAF and serous adenocarcinoma: After adjusting for age and stage, compared to wildtype SBTs, the risk of subsequent serous carcinoma remains significantly lower among women with BRAF-mutated SBTs [HR 0.27 (0.08 – 0.93), p = 0.038] (Table 2).